TABLE 3.
Peptide group | IFN-γ (pg/ml) for patient:
|
Total no. of responsive patients | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | ||
I | 108 | 310 | 83 | 67 | —b | — | 95 | — | 171 | — | — | 6 |
II | — | 141 | 86 | 41 | — | — | 71 | — | 195 | — | — | 5 |
III | — | 38 | 61 | — | — | — | 28 | — | 208 | 26 | 21 | 6 |
IV | 60 | 98 | — | 49 | — | — | 101 | — | 131 | — | — | 5 |
V | — | 301 | — | 56 | — | — | 28 | — | 176 | — | — | 4 |
VI | 217 | 161 | — | 27 | — | — | 30 | — | 149 | — | — | 5 |
VII | — | 262 | — | 38 | — | — | — | — | 123 | — | — | 3 |
VIII | — | 124 | 138 | 45 | — | — | — | — | 131 | — | 29 | 5 |
PBMC from patients 6 through 16 were stimulated with groups of peptides as described in Material and Methods. After 5 days of antigenic stimulation, supernatants were harvested and IFN-γ levels were measured by ELISA.
—, <20 pg/ml.